美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Veraxa Biotech Holding AG

1.96

+0.01000.51%

成交量：17.10萬

成交額：32.46萬

市值：2.77億

市盈率：9.15

高：2.00

開：1.98

低：1.85

收：1.95

52周最高：27.36

52周最低：1.70

股本：1.41億

流通股本：4,101.25萬

量比：6.32

換手率：0.42%

股息：- -

股息率：- -

每股收益(TTM):0.2142

每股收益(LYR):-2.2094

淨資產收益率：-65.29%

總資產收益率：-20.46%

市淨率：7.16

市盈率(LYR):-0.89

資料載入中...

總覽公司新聞資訊公告

公司資料

公司名字：

Veraxa Biotech Holding AG

交易所：

NASDAQ

成立時間：

2021

員工人數：

- -

公司地址：

Im Neuenheimer Feld 584,Heidelberg,Baden-Württemberg,Germany

官網：

http://www.veraxa.com

郵編：

69120

電話：

49 6221 3521330

傳真：

- -

簡介：

Veraxa Biotech AG於2025年6月25日在瑞士法律下註冊成立。該公司是一家專註於腫瘤學的生物技術公司，擁有急性髓系白血病的臨床項目，以及用於開發抗體藥物偶聯物和T細胞銜接器的專有平台技術。其目標是建立一個腫瘤學項目管線，旨在為患者實現療效的同時最大限度地減少副作用。

董事

名稱

職位

Adeel Rouf

President, Chief Executive Officer and Director

Warren Hosseinion

Chairman of the Board and Director

Jonathan Intrater

Independent Director

Oded Levy

Independent Director

股東

名稱

職位

Adeel Rouf

President, Chief Executive Officer and Director

Carl von Halem

Interim Chief Financial Officer

Christoph Erkel

Chief Scientific Officer

Warren Hosseinion Jr.

Vice President, Mergers and Acquisitions

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/stock/VRXA/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"VRXA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"VRXA\",,,,,undefined,":{"symbol":"VRXA","market":"US","secType":"STK","nameCN":"Veraxa Biotech Holding AG","latestPrice":1.96,"timestamp":1787588248758,"preClose":1.95,"halted":0,"volume":171037,"delay":0,"changeRate":0.0051282051282051325,"floatShares":41012504,"shares":141407813,"eps":0.2142,"marketStatus":"交易中","change":0.01,"latestTime":"08-24 12:21:22 EDT","open":1.98,"high":2,"low":1.85,"amount":324616.5612766,"amplitude":0.076923,"askPrice":2,"askSize":400,"bidPrice":1.94,"bidSize":159,"shortable":3,"etf":0,"ttmEps":0.2142,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1787601600000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":1.95,"preHourTrading":{"tag":"盘前","latestPrice":2.02,"preClose":1.95,"latestTime":"09:15 EDT","volume":2114,"amount":4245.3946262,"timestamp":1787577340602,"change":0.07,"changeRate":0.035897,"amplitude":0.081744},"postHourTrading":{"tag":"盘后","latestPrice":1.95,"preClose":1.95,"latestTime":"19:02 EDT","volume":146,"amount":283.17,"timestamp":1787353358074,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":6.322923},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"VRXA\",,,,,undefined,":{"symbol":"VRXA","floatShares":41012504,"roa":"-20.46%","roe":"-65.29%","lyrEps":-2.209413,"volumeRatio":6.322923,"shares":141407813,"dividePrice":0,"high":2,"amplitude":0.076923,"preClose":1.95,"low":1.85,"week52Low":1.7,"pbRate":"7.16","week52High":27.36,"institutionHeld":0,"latestPrice":1.96,"committee":-0.431127,"eps":0.2142,"divideRate":0,"volume":171037,"delay":0,"ttmEps":0.2142,"open":1.98,"prevYearClose":18.65,"prevWeekClose":1.95,"prevMonthClose":1.76,"prevQuarterClose":1.88,"fiveDayClose":1.86,"twentyDayClose":2.01},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/VRXA\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"VRXA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"VRXA\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/VRXA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"VRXA","date":"2026-08-21","current":9.103641,"percent":0,"low":-1.35335,"twenty":-1.349054,"median":-1.34261,"eighty":-1.336165,"high":-1.331869,"avg":-1.34261,"sd":0.010741,"marketCap":47660725},"quantilePoints":[{"date":"2026-08-21","current":-1.35335,"twenty":-1.349054,"median":-1.34261,"eighty":-1.336165,"marketCap":47660725}],"updateTime":1787558428202},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":699307581,"yearFounded":2021,"address":"Im Neuenheimer Feld 584,Heidelberg,Baden-Württemberg,Germany","zipCode":"69120","officePhone":"49 6221 3521330"},"stockCompanyDetail":{"websiteUrl":"http://www.veraxa.com","stockEarnings":[{"period":"1week","weight":0.0428},{"period":"1month","weight":-0.0488},{"period":"3month","weight":-0.8954},{"period":"ytd","weight":-0.8954}],"compareEarnings":[{"period":"1week","weight":-0.0137},{"period":"1month","weight":0.0245},{"period":"3month","weight":0.0269},{"period":"6month","weight":0.1107},{"period":"1year","weight":0.2048},{"period":"ytd","weight":0.1229}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"Veraxa Biotech AG於2025年6月25日在瑞士法律下註冊成立。該公司是一家專註於腫瘤學的生物技術公司，擁有急性髓系白血病的臨床項目，以及用於開發抗體藥物偶聯物和T細胞銜接器的專有平台技術。其目標是建立一個腫瘤學項目管線，旨在為患者實現療效的同時最大限度地減少副作用。","exchange":"NASDAQ","name":"Veraxa Biotech Holding AG","nameEN":"Veraxa Biotech Holding AG"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"VRXA\",market:\"US\",,,undefined,":{"directors":[{"name":"Adeel Rouf","position":"President, Chief Executive Officer and Director"},{"name":"Warren Hosseinion","position":"Chairman of the Board and Director"},{"name":"Jonathan Intrater","position":"Independent Director"},{"name":"Oded Levy","position":"Independent Director"}],"executives":[{"name":"Adeel Rouf","position":"President, Chief Executive Officer and Director"},{"name":"Carl von Halem","position":"Interim Chief Financial Officer"},{"name":"Christoph Erkel","position":"Chief Scientific Officer"},{"name":"Warren Hosseinion Jr.","position":"Vice President, Mergers and Acquisitions"}]}}}